The biotech's candidate may treat a great number of illnesses that have one thing in common.

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...

Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for ...

Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

Science and medicine are incredibly amazing. Thanks to modern science and medicine, we now have lifespans far beyond our Dark Age predecessors, living until ripe old age and enjoying the fruits of our ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $50.71, marking a -2.59% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.04%.

Whales with a lot of money to spend have taken a noticeably bearish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 13 trades. If we ...